HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Akihiko Usui Mitsuya Murase Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Usui, A. Articles by Murase, M. Search for Related Content PubMed PubMed Citation Articles by Usui, A. Articles by Murase, M.

Ann Thorac Surg 1996;62:1404-1411
© 1996 The Society of Thoracic Surgeons

---

Original Article: Cardiovascular

Nafamostat Mesilate Reduces Blood–Foreign Surface Reactions Similar to Biocompatible Materials

Division of Cardiac Surgery, Cardiovascular Center, Owari Prefectural Hospital, and Department of Thoracic Surgery, Nagoya University, School of Medicine, Aichi, Japan

Accepted for publication June 15, 1996.

Background. Nafamostat mesilate (FUT-175) is a synthetic serine protease inhibitor that inactivates coagulation, fibrinolysis, and platelet aggregation. Nafamostat mesilate may suppress the blood–foreign surface reaction similar to biocompatible materials by blocking factor XIIa.

Methods. We performed an in vitro study of cardiopulmonary bypass (CPB) with fresh human blood among the following three groups: standard CPB sets (C), biocompatible CPB sets (B), and standard CPB sets with FUT-175 (10 mg/L) (F). A clinical study using these same CPB groups also was performed in 45 patients undergoing aortocoronary bypass operations (15 patients each). We injected FUT-175 at 40 mg/h during CPB.

Results. In the in vitro study, both groups B and F showed significantly lower levels of coagulation factors, thrombin-antithrombin III complex, fibrinopeptide A, ß-thromboglobulin, complement C3a, granulocyte elastase, and free hemoglobin than group C at the conclusion of the study. Thrombin-antithrombin III complex and free hemoglobin in group F also were lower than in group B. The platelet count remained at a higher level in group F than in the other groups. Separation of bradykinin was suppressed most significantly in group F. In the clinical study, group F also showed significantly lower levels of 2-plasmin inhibitor plasmin complex and C3a than both groups C and B. There were minimal levels of free hemoglobin in group F.

Conclusions. Nafamostat mesilate may contribute major beneficial effects toward conservation of blood during CPB and prevention of coagulopathy after CPB.

This article has been cited by other articles:

				Y. Hiramatsu, S. Homma, Y. Sato, S. Sato, K. Matsuzaki, O. Shigeta, and Y. Sakakibara Nafamostat Preserves Neutrophil Deformability and Reduces Microaggregate Formation During Simulated Extracorporeal Circulation Ann. Thorac. Surg., April 1, 2005; 79(4): 1326 - 1332. [Abstract] [Full Text] [PDF]

				Y. Kaminishi, Y. Hiramatsu, Y. Watanabe, Y. Yoshimura, and Y. Sakakibara Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2004; 77(2): 644 - 650. [Abstract] [Full Text] [PDF]

				T. Yamazaki, H. Ooshima, A. Usui, T. Watanabe, and K. Yasuura Protective effects of ONO-5046{middle dot}Na, a specific neutrophil elastase inhibitor, on postperfusion lung injury Ann. Thorac. Surg., December 1, 1999; 68(6): 2141 - 2146. [Abstract] [Full Text] [PDF]

				C. Baufreton, M. Kirsch, and D. Y. Loisance Measures to control blood activation during assisted circulation Ann. Thorac. Surg., November 1, 1998; 66(5): 1837 - 1844. [Abstract] [Full Text] [PDF]